Metabolism: MAFLD and CKD Risk

Non-alcoholic fatty liver disease (NAFLD) is a multi-system disease, and the association between metabolic dysfunction-related fatty liver disease (MAFLD) and liver disease is not clear.
recently, a study published in Metabolic Diseases, an authoritative journal, Metabolic Diseases, looked at the relationship between the presence and severity of MAFLD and proteinuria by comparing the prevalence of chronic kidney disease (CKD) in patients with MAFLD or NAFLD.
researchers analyzed 12,571 participants from the Third National Health and Nutrition Examination Survey (1988-1994) with complete bio-bio-chemical and liver ultrasound data.
researchers conducted a multivariate logistic regression analysis to assess the correlation between MAFLD or MAFLD severity and critical exposure and CKD (defined as CKD≥1 or ≥3 stages) or proteinuria (urinary albumin-to-creatinine ratio ≥3mg/mmol).
prevalence of MAFLD and NAFLD was 30.2% (n-3794) and 36.2% (n-4552), respectively.
eGFR was lower in patients with MAFLD (74.96±18.21 vs. 76.46±18.24mL/min/1.73m2, P.lt;0.001), higher prevalence of CKD (29.60% vs. 26.56%, P.lt;0.05).
, the prevalence of CKD was higher in MAFLD patients than in NAFLD, which is associated with non-metabolic dysfunction.
notably, the severity of MAFLD (i.e., NAFLD fibrosis score ≥0.676) was associated with a 1.34-fold increase in the risk of CKD after adjusting for gender, age, race, alcohol consumption and diabetes.
result, MAFLD's ability to identify CKD patients is superior to NAFLD's.
MAFLD and increased liver fibrosis scores were closely related to CKD and proteinuria.